WAM
LJPC

Wealthspire Advisors (Maryland)’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-375
Closed -$2K – 2538
2019
Q1 		$2K Buy
+375
New +$2.44K ﹤0.01% 2274

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s LJPC Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2019, closing a stake of 375 shares — an estimated $2K sold.

Wealthspire Advisors (Maryland) first reported a position in LJPC in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 80 funds tracked by Wall St. Rank hold LJPC as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining La Jolla Pharmaceutical Company position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 375 La Jolla Pharmaceutical Company shares in Q2 2019, an estimated $2K.
  • Wealthspire Advisors (Maryland) first reported a position in La Jolla Pharmaceutical Company in Q1 2019 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s La Jolla Pharmaceutical Company position peaked at $2K in Q1 2019.
  • 80 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.